Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | SVP,ChiefCompliance&EthicsOff. | July 30, 2021 | August 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date July 30, 2021 · Filed August 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 13,777.152 |
Reported balance
After 2021-07-30 transaction · row 1
1 source rowRow 1 · 2021-07-30 · Sale · Disposed 2,466 · Balance 13,777.152 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.905 to $67.910, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBMS Savings and Investment Program | 971.87 |
Reported balance
Holding disclosure · report date 2021-07-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 971.87 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.905 to $67.910, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 72,694 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-10-30 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 309,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 105,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 8,889 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F10: The Restricted Stock Units ("RSUs") vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vests in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 5,250 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-23 · Disposition to issuer · Disposed 25,816 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-23 · Disposition to issuer · Disposed 40,565 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-23 · Disposition to issuer · Disposed 65,625 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F7: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F8: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F10: The Restricted Stock Units ("RSUs") vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vests in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.
F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,626 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,878 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,778 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013682 · form4-05192025_090500.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 4,646 | $11.96 | $55,580.10 |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · nonDerivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,602 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.86 to $12.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,313 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,565 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,740 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2025 Filed Feb 21, 2025 23:08 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-005157 · form4-02212025_110227.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 15, 2025 Filed Jan 31, 2025 21:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002483 · form4-01312025_090155.xml · derivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| January 15, 2025 Filed Jan 31, 2025 21:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 90,000 | $0.00 Strike: $11.87 | $0.00 |
DisclosureSEC source: 0001415889-25-002483 · form4-01312025_090155.xml · derivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-01-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,165 | $13.21 | $41,810.28 |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,162 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $13.02 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,252 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,702 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:32 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027229 · form4-11192024_091102.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,202 | $14.00 | $44,825.12 |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,928 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,939 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,664 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021629 · form4-08192024_100841.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,253 | $16.08 | $52,304.01 |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,731 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,626 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,626 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-013614 · form4-05172024_100516.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,242 | $15.25 | $49,434.34 |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,585 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,313 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,250 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,588 Underlying: Common Stock · 2,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 3,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004473 · form4-02202024_110256.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:25 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001293 · doc4.xml · derivative · entry 2 Dubow Adam · CIK 0001744507 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:25 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 90,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001209191-24-001293 · doc4.xml · derivative · entry 1 Dubow Adam · CIK 0001744507 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 23:30 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 5,313 | $11.69 | $62,108.97 |
DisclosureSEC source: 0001209191-23-055889 · doc4.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,428 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.